Barry Hudson, Ph.D.
- Assistant Professor
- Co-Director of Clinical and Translational Investigation Masterís Program
Diabetes, cardiovascular disease, inflammation and breast cancer
Stanley Glaser award
University of Leeds
University of Leeds
- Hudson BI, Gardener H, Liu-Mares W, Dong C, Cespedes S, Elkind MS, Wright CB, Sacco RL, Rundek T. (2015) Soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS) Atherosclerosis 240(1):17-20
- Hudson BI, Dong C, Gardener H, Elkind MS, Wright CB, Goldberg R, Sacco RL, Rundek T. (2014) Serum levels of soluble Receptor for Advanced Glycation End-products and metabolic syndrome: the Northern Manhattan Study. Metabolism 63 (9): 1125-1130
- Tiozzo E, Gardener H, Hudson BI, Dong C, Della Morte D, Crisby M, Elkind MS, Cheung YK, Wright CB, Goldberg R, Sacco RL, Rundek T. (2014) High-density lipoprotein subfractions and carotid plaque: The Northern Manhattan Study. Atherosclerosis 237 (1): 163-168
- Wang L, Rundek T, Beecham A, Hudson B, Blanton SH, Zhao H, Sacco RL, Dong C. (2014) Genome-wide interaction study identifies RCBTB1 as a modifier for smoking effect on carotid intima-media thickness. ATVB 34(1):219-25
- Gardener H, Crisby M, Sjoberg C, Hudson B, Goldberg R, Mendez AJ, Wright CB, Rundek T, Elkind MS, Sacco RL. (2013) Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. Metab Syndr Relat Disord. 11(1):46-55
- Jules J, Miaguel D, Hudson BI*. (2013) Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLOS ONE 8;8(11):e78267
- Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, Paik MC, Yoshita M, Sacco RL, DeCarli C, Wright CB, Elkind MS (2011) Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis. 216(1):192-8
- Pubmed link to publications
My research has sought to understand the role of RAGE (Receptor for Advanced Glycation End-products) and its ligands in the development of inflammatory disease states including diabetes and breast cancer. During my PhD, I identified SNPs of the RAGE gene, linked them to the severity of CVD and diabetes and elucidated their function. A number of these SNPs have emerged as markers for cardiovascular disease, pulmonary disease and various cancers in humans. As a postdoc I explored the vascular and tumor biology of RAGE, in the lab of Dr. Ann Marie Schmidt. Dr. Schmidt not only discovered RAGE, but pioneered definitive studies demonstrating a role for RAGE in diabetes and cardiovascular disease. During this period I expanded my training into tumor biology of RAGE where I; (1) established that RAGE induces tumor cell signaling and activation through directly binding mDia1, (2) elucidated the post-transcriptional regulation of RAGE and its role in tumorigenesis, (3) performed translational studies in human cohorts to study the role of serum RAGE levels as a biomarker of cardiovascular disease.
As a Research Assistant Professor at the University of Miami, I have built on my prior work and developed a research program focused on elucidating how RAGE drives breast cancer progression and metastasis. My work has demonstrated that inhibition of RAGE signaling, reduces tumor growth and metastasis, due to profound decreases in tumor cell migration and invasion capacity. To translate these findings into a possible cancer therapy, we are now testing novel RAGE and RAGE-ligand inhibitors for their effects on tumor metastases. My current and future plans are focused on (1) how inflammation increases breast cancer metastasis, and (2) the role of obesity and diabetes in driving breast cancer progression and metastasis. In the long term I hope my work will change the clinical management of breast cancer and result in an effective therapy to help treat this deadly disease.